Ser527
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser527  -  PML (human)

Site Information
PHLDGPPsPRsPVIG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451472
Available spectra:  7 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 64 , 65 )
Disease tissue studied:
breast cancer ( 4 , 11 , 12 , 31 , 32 ) , breast ductal carcinoma ( 11 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 11 ) , cervical cancer ( 54 ) , cervical adenocarcinoma ( 54 ) , leukemia ( 36 , 60 , 61 , 62 ) , acute myelogenous leukemia ( 36 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 30 ) , acute megakaryoblastic leukemia (M7) ( 30 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 30 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 30 ) , acute myeloblastic leukemia, without maturation (M1) ( 30 ) , chronic myelogenous leukemia ( 60 , 61 , 62 ) , hepatocellular carcinoma, surrounding tissue ( 52 ) , lung cancer ( 8 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 32 , 44 ) , non-small cell lung cancer ( 18 , 19 , 21 , 22 , 23 , 27 , 28 , 32 ) , non-small cell lung adenocarcinoma ( 8 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 28 , 44 ) , non-small cell large cell lung carcinoma ( 18 , 21 ) , non-small cell squamous cell lung carcinoma ( 20 ) , small-cell lung cancer ( 17 ) , lymphoma ( 13 ) , B cell lymphoma ( 30 ) , Burkitt's lymphoma ( 13 ) , non-Hodgkin's lymphoma ( 30 ) , follicular lymphoma ( 13 ) , mantle cell lymphoma ( 13 ) , ovarian cancer ( 11 ) , pancreatic ductal adenocarcinoma ( 16 ) , multiple myeloma ( 30 ) , melanoma skin cancer ( 7 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 37 ) , 'pancreatic, ductal'-pancreas ( 16 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 48 ) , 293 (epithelial) ( 10 ) , 293E (epithelial) ( 40 ) , 786-O (renal) [VHL (human), transfection] ( 5 ) , 786-O (renal) ( 5 ) , A431 (epithelial) ( 65 ) , A498 (renal) ( 50 ) , AML-193 (monocyte) ( 30 ) , BJAB (B lymphocyte) ( 13 ) , breast ( 2 , 11 ) , BT-20 (breast cell) ( 32 ) , BT-474 (breast cell) ( 4 ) , BT-549 (breast cell) ( 32 ) , Cal-12T (pulmonary) ( 23 ) , Calu 6 (pulmonary) ( 32 ) , Calu-3 (pulmonary) ( 19 ) , CMK (megakaryoblast) ( 30 ) , CTS (myeloid) ( 30 ) , DMS153 (pulmonary) ( 22 ) , DMS53 (pulmonary) ( 17 ) , DOHH2 ('B lymphocyte, precursor') ( 30 ) , endothelial-aorta ( 33 ) , FL-18 (B lymphocyte) ( 13 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 34 ) , Flp-In T-Rex-293 (epithelial) ( 34 ) , GM00130 (B lymphocyte) ( 49 ) , H2009 (pulmonary) ( 32 ) , H2077 (pulmonary) ( 32 ) , H2887 (pulmonary) ( 32 ) , H322M (pulmonary) ( 32 ) , HCC1359 (pulmonary) ( 32 ) , HCC15 (pulmonary) ( 20 ) , HCC1937 (breast cell) ( 32 ) , HCC2279 (pulmonary) ( 32 ) , HCC366 (pulmonary) ( 32 ) , HCC4006 (pulmonary) ( 32 ) , HCC44 (pulmonary) ( 23 ) , HCC78 (pulmonary) ( 21 , 32 ) , HCC827 (pulmonary) ( 19 , 32 ) , HEK293T (epithelial) ( 6 ) , HEL (erythroid) ( 30 ) , HeLa (cervical) ( 1 , 9 , 29 , 47 , 55 , 59 , 64 ) , HeLa S3 (cervical) ( 45 , 54 ) , hepatocyte-liver ( 52 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 12 ) , HMLER ('stem, breast cancer') ( 12 ) , HOP62 (pulmonary) ( 32 ) , HUES-9 ('stem, embryonic') ( 46 ) , JEKO-1 (B lymphocyte) ( 13 ) , Jurkat (T lymphocyte) ( 25 , 38 , 39 , 41 , 42 , 43 , 51 , 56 , 57 , 58 ) , K562 (erythroid) ( 29 , 55 , 60 , 61 , 62 ) , Kasumi-1 (myeloid) ( 30 ) , KG-1 (myeloid) ( 30 , 36 ) , LCLC-103H (pulmonary) ( 32 ) , leukocyte-blood ( 53 ) , liver ( 15 ) , LOU-NH91 (squamous) ( 20 , 32 ) , lung ( 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , MCF-7 (breast cell) ( 4 , 32 ) , MDA-MB-231 (breast cell) ( 32 ) , MDA-MB-468 (breast cell) ( 32 ) , MV4-11 (macrophage) ( 30 ) , NCEB-1 (B lymphocyte) ( 13 ) , NCI-H1299 (pulmonary) ( 18 ) , NCI-H1395 (pulmonary) ( 32 ) , NCI-H1437 (pulmonary) ( 22 , 23 ) , NCI-H1568 (pulmonary) ( 32 ) , NCI-H157 (pulmonary) ( 32 ) , NCI-H1648 (pulmonary) ( 32 ) , NCI-H1650 (pulmonary) ( 19 ) , NCI-H1666 (pulmonary) ( 23 , 32 ) , NCI-H1703 (squamous) ( 20 ) , NCI-H1734 (pulmonary) ( 18 ) , NCI-H1781 (pulmonary) ( 21 ) , NCI-H1944 (pulmonary) ( 18 ) , NCI-H1975 (pulmonary) ( 19 ) , NCI-H2030 (pulmonary) ( 32 ) , NCI-H2073 (pulmonary) ( 20 , 22 ) , NCI-H209 (pulmonary) ( 22 ) , NCI-H2106 (pulmonary) ( 19 ) , NCI-H2172 (pulmonary) ( 32 ) , NCI-H2228 (pulmonary) ( 21 , 28 ) , NCI-H2342 (pulmonary) ( 20 ) , NCI-H2405 (pulmonary) ( 23 ) , NCI-H3122 (pulmonary) ( 21 , 27 ) , NCI-H322 (pulmonary) ( 32 ) , NCI-H358 (pulmonary) ( 18 ) , NCI-H446 (pulmonary) ( 17 ) , NCI-H460 (pulmonary) ( 18 , 32 ) , NCI-H520 (squamous) ( 32 ) , NCI-H526 (pulmonary) ( 17 ) , NCI-H647 (pulmonary) ( 32 ) , NCI-H661 (pulmonary) ( 21 ) , NCI-H69 (pulmonary) ( 17 ) , NCI-H82 (pulmonary) ( 17 ) , NCI-H838 (pulmonary) ( 22 ) , OCI-ly1 (B lymphocyte) ( 13 ) , OPM-2 (plasma cell) ( 30 ) , ovary ( 11 ) , P31/FUJ (erythroid) ( 30 ) , PC9 (pulmonary) ( 8 , 32 ) , PC9-IR (pulmonary) ( 8 ) , REC-1 (B lymphocyte) ( 13 ) , RL ('B lymphocyte, precursor') ( 30 ) , RPMI-8266 (plasma cell) ( 30 ) , SH-SY5Y (neural crest) ( 14 ) , SKBr3 (breast cell) ( 31 ) , SU-DHL-6 (B lymphocyte) ( 30 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 44 ) , U-1810 (pulmonary) ( 44 ) , U266 (plasma cell) ( 30 ) , WM239A (melanocyte) ( 7 )

Upstream Regulation
Treatments:
angiotensin-(1-7) ( 33 ) , angiotensin_2 ( 48 ) , anti-CD3 ( 58 ) , dasatinib ( 55 ) , EGF ( 1 , 55 ) , LRRK2-IN-1 ( 14 ) , nocodazole ( 54 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

6

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

7

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

8

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

9

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

10

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

11

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

12

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

13

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

14

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

15

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

16

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

17

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

18

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

19

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

20

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

21

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

22

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

23

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

24

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

25

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

26

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

27

Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

28

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

29

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

30

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

31

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

32

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

33

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

34

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

35

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

36

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

37

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

38

Mulhern D (2011) CST Curation Set: 12712; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

39

Guo A (2011) CST Curation Set: 12019; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

40

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

41

Guo A (2011) CST Curation Set: 12065; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

42

Guo A (2011) CST Curation Set: 12066; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

43

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

44

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

45

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

46

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

47

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

48

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

49

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

50

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

51

Possemato A (2010) CST Curation Set: 9290; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

52

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

53

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

54

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

55

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

56

Possemato A (2009) CST Curation Set: 8350; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info

57

Guo A (2009) CST Curation Set: 8004; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

59

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

60

Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

62

Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

63

Tagata Y, et al. (2008) Phosphorylation of PML is essential for activation of C/EBP epsilon and PU.1 to accelerate granulocytic differentiation. Leukemia 22, 273-80
17989716   Curated Info

64

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info

65

MS This site is one of 509 sites observed by D. Stover et al using MS/FTMS of peptides from lysates of A431 cells grown either in vitro or as xenografts in BALB/c nu/nu mice. These sites were previously unpublished until now (July 27 2006). 66 sites were previously published in: Stover DR, et al. Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts Clin Proteomics 2004 Mar 01; 1(1): 69-80.
Curated Info